The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies
Abstract
The design of a human immunodeficiency virus–1 (HIV-1) immunogen that can induce broadly reactive neutralizing antibodies is a major goal of HIV-1 vaccine development. Although rare human monoclonal antibodies (mAbs) exist that broadly neutralize HIV-1, HIV-1 envelope immunogens do not induce these antibody specificities. Here we demonstrate that the two most broadly reactive HIV-1 envelope gp41 human mAbs, 2F5 and 4E10, are polyspecific autoantibodies reactive with the phospholipid cardiolipin. Thus, current HIV-1 vaccines may not induce these types of antibodies because of autoantigen mimicry of the conserved membrane-proximal epitopes of the virus. These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martin, F., Oliver, A. M., & Kearney, J. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00129-7 · Cited by 985
Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition
Calarese, D. A., Scanlan, C. N., Zwick, M. B., Deechongkit, S., Mimura, Y., Kunert, R., Zhu, P., Wormald, M. R., Stanfield, R. L., Roux, K. H., et al. (2003) · Science · doi:10.1126/science.1083182 · Cited by 781
Self-citationHIV vaccine design and the neutralizing antibody problem
Burton, D. R., Desrosiers, R. C., Doms, R. W., Koff, W. C., Kwong, P. D., Moore, J. P., Nabel, G. J., Sodroski, J., Wilson, I. A., & Wyatt, R. T. (2004) · Nature Immunology · doi:10.1038/ni0304-233 · Cited by 765
Bevers, E. M., Galli, M., Barbui, T., Comfurius, P., & Zwaal, R. F. A. (1991) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646476 · Cited by 576
Cardoso, R. M. F., Zwick, M. B., Stanfield, R. L., Kunert, R., Binley, J. M., Katinger, H., Burton, D. R., & Wilson, I. A. (2005) · Immunity · doi:10.1016/j.immuni.2004.12.011 · Cited by 449
Self-citationDelgado Alves, J., Ames, P. R. J., Donohue, S., Stanyer, L., Noorouz‐Zadeh, J., Ravirajan, C., & Isenberg, D. A. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10542 · Cited by 199
Meffre, E., Milili, M., Blanco-Betancourt, C., Antunes, H., Nussenzweig, M. C., & Schiff, C. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13051 · Cited by 152
Barbato, G., Bianchi, E., Ingallinella, P., Hurni, W. H., Miller, M. D., Ciliberto, G., Cortese, R., Bazzo, R., Shiver, J. W., & Pessi, A. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00611-9 · Cited by 136
Petrovas, C., Vlachoyiannopoulos, P. G., Kordossis, T., & Moutsopoulos, H. Μ. (1999) · Journal of Autoimmunity · doi:10.1006/jaut.1999.0324 · Cited by 103
McGaughey, G. B., Citron, M. P., Danzeisen, R. C., Freidinger, R. M., Garsky, V. M., Hurni, W. M., Joyce, J. G., Liang, X., Miller, M. D., Shiver, J. W., et al. (2003) · Biochemistry · doi:10.1021/bi026952u · Cited by 103
Cited by
mTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575
Broad neutralization coverage of HIV by multiple highly potent antibodies
Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J.-P., Wang, S.-K., Ramos, A., Chan-Hui, P.-Y., Moyle, M., et al. (2011) · Nature · doi:10.1038/nature10373 · Cited by 1,480
Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
Zhou, T., Georgiev, I., Wu, X., Yang, Z.-Y., Dai, K., Finzi, A., Do Kwon, Y., Scheid, J. F., Shi, W., Xu, L., et al. (2010) · Science · doi:10.1126/science.1192819 · Cited by 1,130
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Liao, H.-X., Lynch, R., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., Fire, A. Z., Roskin, K. M., Schramm, C. A., Zhang, Z., et al. (2013) · Nature · doi:10.1038/nature12053 · Cited by 988
Self-citationBroad and potent neutralization of HIV-1 by a gp41-specific human antibody
Huang, J., Ofek, G., Laub, L., Louder, M. K., Doria-Rose, N. A., Longo, N. S., Imamichi, H., Bailer, R. T., Chakrabarti, B., Sharma, S. K., et al. (2012) · Nature · doi:10.1038/nature11544 · Cited by 828
Self-citationThrosby, M., van den Brink, E., Jongeneelen, M., Poon, L. L. M., Alard, P., Cornelissen, L., Bakker, A., Cox, F., van Deventer, E., Guan, Y., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003942 · Cited by 737
Comprehensive mapping of immune perturbations associated with severe COVID-19
Kuri-Cervantes, L., Pampena, M. B., Meng, W., Rosenfeld, A. M., Ittner, C. A. G., Weisman, A. R., Agyekum, R. S., Mathew, D., Baxter, A. E., Vella, L. A., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd7114 · Cited by 723
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., DeKosky, B. J., Ernandes, M. J., Georgiev, I. S., Kim, H. J., Pancera, M., et al. (2014) · Nature · doi:10.1038/nature13036 · Cited by 709
B cells in HIV infection and disease
Moir, S., & Fauci, A. S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2524 · Cited by 702
Translating Innate Immunity into Immunological Memory: Implications for Vaccine Development
Pulendran, B., & Ahmed, R. (2006) · Cell · doi:10.1016/j.cell.2006.02.019 · Cited by 625
Antibody-based protection against HIV infection by vectored immunoprophylaxis
Balazs, A. B., Chen, J., Hong, C. M., Rao, D. S., Yang, L., & Baltimore, D. (2012) · Nature · doi:10.1038/nature10660 · Cited by 545
Mechanisms of central tolerance for B cells
Nemazee, D. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.19 · Cited by 539
Sather, D. N., Armann, J., Ching, L. K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S., Kalams, S., et al. (2009) · Journal of Virology · doi:10.1128/jvi.02036-08 · Cited by 528
B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study
Haynes, B. F., Kelsoe, G., Harrison, S. C., & Kepler, T. B. (2012) · Nature Biotechnology · doi:10.1038/nbt.2197 · Cited by 486
Self-citationAutoreactivity in Human IgG+ Memory B Cells
Tiller, T., Tsuiji, M., Yurasov, S., Velinzon, K., Nussenzweig, M. C., & Wardemann, H. (2007) · Immunity · doi:10.1016/j.immuni.2007.01.009 · Cited by 478
HIV‐1 neutralizing antibodies: understanding nature's pathways
Mascola, J. R., & Haynes, B. F. (2013) · Immunological Reviews · doi:10.1111/imr.12075 · Cited by 475
Self-citationBroadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Natural polyreactive IgA antibodies coat the intestinal microbiota
Bunker, J. J., Erickson, S. A., Flynn, T. M., Henry, C., Koval, J. C., Meisel, M., Jabri, B., Antonopoulos, D. A., Wilson, P. C., & Bendelac, A. (2017) · Science · doi:10.1126/science.aan6619 · Cited by 468
Antibodies in HIV-1 Vaccine Development and Therapy
Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L., & Nussenzweig, M. C. (2013) · Science · doi:10.1126/science.1241144 · Cited by 457
Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies
Kwong, P. D., & Mascola, J. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.012 · Cited by 455
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
Stamatatos, L., Morris, L., Burton, D. R., & Mascola, J. R. (2009) · Nature Medicine · doi:10.1038/nm.1949 · Cited by 430
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation
Mouquet, H., Scheid, J. F., Zoller, M. J., Krogsgaard, M., Ott, R. G., Shukair, S., Artyomov, M. N., Pietzsch, J., Connors, M., Pereyra, F., et al. (2010) · Nature · doi:10.1038/nature09385 · Cited by 427
Corti, D., Langedijk, J. P. M., Hinz, A., Seaman, M. S., Vanzetta, F., Fernandez-Rodriguez, B. M., Silacci, C., Pinna, D., Jarrossay, D., Balla-Jhagjhoorsingh, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008805 · Cited by 426
Bonsignori, M., Hwang, K.-K., Chen, X., Tsao, C.-Y., Morris, L., Gray, E., Marshall, D. J., Crump, J. A., Kapiga, S. H., Sam, N. E., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05045-11 · Cited by 423
Self-citationBroad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface
Huang, J., Kang, B. H., Pancera, M., Lee, J. H., Tong, T., Feng, Y., Imamichi, H., Georgiev, I. S., Chuang, G.-Y., Druz, A., et al. (2014) · Nature · doi:10.1038/nature13601 · Cited by 420
Self-citationHIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies
Steichen, J. M., Kulp, D. W., Tokatlian, T., Escolano, A., Dosenovic, P., Stanfield, R. L., McCoy, L. E., Ozorowski, G., Hu, X., Kalyuzhniy, O., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.016 · Cited by 401
The Role of Antibodies in HIV Vaccines
Mascola, J. R., & Montefiori, D. C. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101256 · Cited by 388
Challenges in the development of an HIV-1 vaccine
Barouch, D. H. (2008) · Nature · doi:10.1038/nature07352 · Cited by 380
A Blueprint for HIV Vaccine Discovery
Burton, D. R., Ahmed, R., Barouch, D. H., Butera, S. T., Crotty, S., Godzik, A., Kaufmann, D. E., McElrath, M. J., Nussenzweig, M. C., Pulendran, B., et al. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.09.008 · Cited by 375
Buonaguro, L., Tornesello, M. L., & Buonaguro, F. M. (2007) · Journal of Virology · doi:10.1128/jvi.00872-07 · Cited by 359
Binley, J. M., Lybarger, E. A., Crooks, E. T., Seaman, M. S., Gray, E., Davis, K. L., Decker, J. M., Wycuff, D., Harris, L., Hawkins, N., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01762-08 · Cited by 355
Self-citationStrategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Haynes, B. F., Wiehe, K., Borrow, P., Saunders, K. O., Korber, B., Wagh, K., McMichael, A. J., Kelsoe, G., Hahn, B. H., Alt, F., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00753-w · Cited by 352
Self-citationLambotte, O., Ferrari, G., Moog, C., Yates, N. L., Liao, H.-X., Parks, R. J., Hicks, C. B., Owzar, K., Tomaras, G. D., Montefiori, D. C., et al. (2009) · AIDS · doi:10.1097/qad.0b013e328329f97d · Cited by 342
Self-citationdeCamp, A., Hraber, P., Bailer, R. T., Seaman, M. S., Ochsenbauer, C., Kappes, J., Gottardo, R., Edlefsen, P., Self, S., Tang, H., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02853-13 · Cited by 330
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Kwong, P. D., Mascola, J. R., & Nabel, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3516 · Cited by 329
Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy
West, A. P., Scharf, L., Scheid, J. F., Klein, F., Bjorkman, P. J., & Nussenzweig, M. C. (2014) · Cell · doi:10.1016/j.cell.2014.01.052 · Cited by 321
Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody
Bonsignori, M., Zhou, T., Sheng, Z., Chen, L., Gao, F., Joyce, M. G., Ozorowski, G., Chuang, G.-Y., Schramm, C. A., Wiehe, K., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.022 · Cited by 319
Self-citationHIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure
Kwong, P. D., & Mascola, J. R. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.029 · Cited by 304
Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection
Gray, E. S., Moore, P. L., Choge, I. A., Decker, J. M., Bibollet-Ruche, F., Li, H., Leseka, N., Treurnicht, F., Mlisana, K., Shaw, G. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.00239-07 · Cited by 299
Antibody vs. HIV in a clash of evolutionary titans
Burton, D. R., Stanfield, R. L., & Wilson, I. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505126102 · Cited by 299
Antibodies and B Cell Memory in Viral Immunity
Dörner, T., & Radbruch, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.002 · Cited by 290
Menard, L., Saadoun, D., Isnardi, I., Ng, Y.-S., Meyers, G., Massad, C., Price, C., Abraham, C., Motaghedi, R., Buckner, J. H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45790 · Cited by 287
Crystal Structure of HIV-1 gp41 Including Both Fusion Peptide and Membrane Proximal External Regions
Buzon, V., Natrajan, G., Schibli, D., Campelo, F., Kozlov, M. M., & Weissenhorn, W. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000880 · Cited by 285
Rudicell, R. S., Kwon, Y. D., Ko, S.-Y., Pegu, A., Louder, M. K., Georgiev, I. S., Wu, X., Zhu, J., Boyington, J. C., Chen, X., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02213-14 · Cited by 282
Self-citationSun, Z.-Y. J., Oh, K. J., Kim, M., Yu, J., Brusic, V., Song, L., Qiao, Z., Wang, J.-H., Wagner, G., & Reinherz, E. L. (2008) · Immunity · doi:10.1016/j.immuni.2007.11.018 · Cited by 279
Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies
Gao, F., Bonsignori, M., Liao, H.-X., Kumar, A., Xia, S.-M., Lu, X., Cai, F., Hwang, K.-K., Song, H., Zhou, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.022 · Cited by 279
Self-citationInduction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination
McElrath, M. J., & Haynes, B. F. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.011 · Cited by 270
Self-citationStructural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16
Pancera, M., Shahzad-ul-Hussan, S., Doria-Rose, N. A., McLellan, J. S., Bailer, R. T., Dai, K., Loesgen, S., Louder, M. K., Staupe, R. P., Yang, Y., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2600 · Cited by 270
Self-citationJayasekera, J. P., Moseman, E. A., & Carroll, M. C. (2007) · Journal of Virology · doi:10.1128/jvi.02128-06 · Cited by 264
Chiorazzi, N., & Ferrarini, M. (2011) · Blood · doi:10.1182/blood-2010-07-155663 · Cited by 264
Alam, S. M., McAdams, M., Boren, D., Rak, M., Scearce, R. M., Gao, F., Camacho, Z. T., Gewirth, D., Kelsoe, G., Chen, P., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4424 · Cited by 260
Self-citationLi, Y., Svehla, K., Louder, M. K., Wycuff, D., Phogat, S., Tang, M., Migueles, S. A., Wu, X., Phogat, A., Shaw, G. M., et al. (2009) · Journal of Virology · doi:10.1128/jvi.01992-08 · Cited by 259
An HIV Vaccine — Evolving Concepts
Johnston, M. I., & Fauci, A. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra066267 · Cited by 257
The majority of intestinal IgA+ and IgG+ plasmablasts in the human gut are antigen-specific
Benckert, J., Schmolka, N., Kreschel, C., Zoller, M. J., Sturm, A., Wiedenmann, B., & Wardemann, H. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44447 · Cited by 256
Montero, M., van Houten, N. E., Wang, X., & Scott, J. K. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00020-07 · Cited by 253
Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01
Li, Y., O'Dell, S., Walker, L. M., Wu, X., Guenaga, J., Feng, Y., Schmidt, S. D., McKee, K., Louder, M. K., Ledgerwood, J. E., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00754-11 · Cited by 235
Self-citationHuman RNA “Rumor” Viruses: the Search for Novel Human Retroviruses in Chronic Disease
Voisset, C., Weiss, R. A., & Griffiths, D. J. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00033-07 · Cited by 157
“An example is the HIV-1 TM (gp41) protein, some epitopes of which mimic sites on phospholipids such as cardiolipin and phosphatidylserine (201).”
BackgroundCharacterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques
Pardi, N., LaBranche, C. C., Ferrari, G., Cain, D. W., Tombácz, I., Parks, R. J., Muramatsu, H., Mui, B. L., Tam, Y. K., Karikó, K., et al. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.03.003 · Cited by 103
Self-citationEnvironmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation
Martirosyan, A., Aminov, R., & Manukyan, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01609 · Cited by 62
Brown, A. J., Snapkov, I., Akbar, R., Pavlović, M., Miho, E., Sandve, G. K., & Greiff, V. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00071b · Cited by 59
Metadata
- Authors
- Haynes, B. F., Fleming, J., St. Clair, E. W., Katinger, H., Stiegler, G., Kunert, R., Robinson, J., Scearce, R. M., Plonk, K., Staats, H. F., Ortel, T. L., Liao, H.-X., & Alam, S. M.
- Venue
- Science
- Published
- 2005-06-24
- Volume
- 308
- Issue
- 5730
- Pages
- 1906-1908
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2097594050
- Cited by
- 744
- References
- 18
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.